Akebia Therapeutics Inc (AKBA) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Akebia Therapeutics Inc   (NASDAQ: AKBA)
 

Akebia Therapeutics Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Akebia Therapeutics Inc inventory turnover ratio, the Akebia Therapeutics Inc 's ability to sell and replace its inventory in the second quarter 2026, sequentially increased to 2.96 in the second quarter 2026, AKBA's markets remain strong, its supply chain continue to be in a grate shape.Average inventory processing period, for the Akebia Therapeutics Inc in Jun 30 2026 quarter, has decreased to 123 days, compare to 132 days, in the Mar 31 2026 quarter.

Within Healthcare sector 134 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1264 in the first quarter 2026, to 1316.

AKBA Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Akebia Therapeutics Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AKBA Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth -22.09 % -34.14 % -3.9 % -9.03 % -30.01 %
Y / Y Cost of Sales Growth 5.09 % 61.18 % -38.45 % -33.74 % -41.81 %
Inventory Turnover Ratio (TTM) 2.96 2.76 2.23 2.65 2.85
AKBA's Total Ranking # 1316 # 1264 # 925 # 762 # 762
Average inventory processing period 123 132 163 138 128
Seq. Inventory Growth 0.17 % -16.75 % -16.27 % 11.58 % -15.33 %
Seq. Cost of Sales Growth -15.18 % -1.95 % 33.59 % -5.4 % 30.09 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 32
Healthcare Sector # 135
Overall Market # 1316

Inventory Turnover Ratio Statistics
High Average Low
4.06 2.87 0.98
(Mar 31 2021)   (Sep 30 2019)



AKBA Company Profile >> Back to AKBA Efficiency Comparisons >> Compare AKBA Inventory Turnover Ratio to its Competitors

Financial Statements
Akebia Therapeutics Inc 's Inventories $ 13 Millions Visit AKBA's Balance sheet
Akebia Therapeutics Inc 's Cost of Revenues TTM $ 45 Millions Visit AKBA's Income Statement
What are AKBA's Sales? Visit AKBA's Sales by Segment

Other Inventory Turnover Ratios
Akebia Therapeutics Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
AKBA's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for AKBA's Competitors
Inventory Turnover Ratio for AKBA's Suppliers
Inventory Turnover Ratio for AKBA's Customers

You may also want to know
AKBA's Sales Growth Rates AKBA's Pe Price to earnings ratio AKBA's Receivables Turnover Ratio AKBA's Stock Quote
AKBA's Net Income Growth Rates AKBA's Ps Price to Sales ratio AKBA's Sales per Employee AKBA's Asset Turnover Ratio
AKBA's Net Margin AKBA's Pb Price to Book ratio AKBA's Financial Strength Ratios AKBA's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Warby Parker Inc   9.27 $ 414.054  Millions$ 45  Millions
Hims and Hers Health Inc   9.23 $ 814.411  Millions$ 88  Millions
Polomar Health Services, Inc.  8.80 $ 1.233  Millions$ 0  Millions
Myriad Genetics Inc   8.31 $ 250.700  Millions$ 30  Millions
National Vision Holdings Inc   8.26 $ 841.416  Millions$ 102  Millions
Autolus Therapeutics Plc  8.08 $ 99.009  Millions$ 12  Millions
The Oncology Institute Inc   8.03 $ 160.655  Millions$ 20  Millions
Nutriband Inc   7.92 $ 1.082  Millions$ 0  Millions
Novavax inc   7.61 $ 88.541  Millions$ 12  Millions
Inogen Inc   7.51 $ 196.617  Millions$ 26  Millions
Moderna Inc   7.50 $ 1,707.000  Millions$ 228  Millions
Cardiff Lexington Corporation  7.49 $ 4.042  Millions$ 1  Millions
Pulse Biosciences Inc   7.45 $ 1.182  Millions$ 0  Millions
Vanda Pharmaceuticals Inc   7.43 $ 13.506  Millions$ 2  Millions
Carlsmed Inc   7.42 $ 13.955  Millions$ 2  Millions
Adaptive Biotechnologies Corporation  7.26 $ 75.254  Millions$ 10  Millions
Lifemd Inc   7.22 $ 22.284  Millions$ 3  Millions
Brightspring Health Services Inc   6.35 $ 4,108.953  Millions$ 647  Millions
Puma Biotechnology Inc   6.29 $ 58.199  Millions$ 9  Millions
Adm Tronics Unlimited Inc   6.05 $ 1.970  Millions$ 0  Millions
Sharps Technology Inc   5.68 $ 2.869  Millions$ 1  Millions
Transmedics Group Inc   5.59 $ 276.120  Millions$ 49  Millions
Cg Oncology Inc   5.47 $ 7.609  Millions$ 1  Millions
Opko Health Inc   5.42 $ 348.206  Millions$ 64  Millions
Charles River Laboratories International inc   5.39 $ 1,761.363  Millions$ 327  Millions
Tactile Systems Technology Inc   5.12 $ 81.349  Millions$ 16  Millions
Integer Holdings Corporation  5.03 $ 1,369.168  Millions$ 272  Millions
Collegium Pharmaceutical Inc   4.99 $ 293.290  Millions$ 59  Millions
Harrow Inc   4.93 $ 73.636  Millions$ 15  Millions
Ufp Technologies Inc   4.93 $ 452.046  Millions$ 92  Millions

Date modified: 2026-09-09T01:58:45+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.